Zobrazeno 1 - 10
of 93
pro vyhledávání: '"David M. Weiss"'
Autor:
David M. Weiss, Elizabeth Bernier, Douglas R. Robbins, Katherine M. Elacqua, Kelsey A. Johnson, Kate Powers, Raquelle I. Mesholam-Gately, Kristen A. Woodberry
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
ObjectivesPsychotic-spectrum disorders emerge during adolescence and early adulthood, which corresponds with the peak period for substance use initiation. Clinical and epidemiological data provide support that substance use is associated with psychot
Externí odkaz:
https://doaj.org/article/350b7ff41b474070b9f8b439fa216867
Autor:
Lisa Hark, Julia A. Haller, Ann P. Murchison, Michael Waisbourd, Eileen L. Mayro, David M. Weiss, Safa Siraj, Carrie Wright, Kathryn Scully, Edward Jaeger
Publikováno v:
Journal of Academic Ophthalmology, Vol 09, Iss 01, Pp e13-e20 (2017)
Abstract Background Over the past 50 years, there has been a decline in the number of physicians pursuing careers in clinical research. In ophthalmology, the need for clinician-investigators continues to grow with the increasing eye-care demands of
Externí odkaz:
https://doaj.org/article/f8f180f4aa404c0a897e5bcc7b0cacf4
Autor:
Arundati Nagendra, David M. Weiss, Carrington Merritt, Corinne Cather, Effua E. Sosoo, Kim T. Mueser, David L. Penn
Publikováno v:
Social Psychiatry and Psychiatric Epidemiology. 58:77-89
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba6e8b6c08b1eaaf021847b37b47834a
https://doi.org/10.1158/2159-8290.c.6547811.v1
https://doi.org/10.1158/2159-8290.c.6547811.v1
Autor:
John C. Byrd, Min-Hui Wang, Cheng Quah, Veerendra Munugalavadla, Raquel Izumi, Ahmed Hamdy, Melanie M. Frigault, Michael Gulrajani, Barbara L. Andersen, David M. Weiss, Gerard Lozanski, Mojgan Jianfar, Seema A. Bhat, Kerry A. Rogers, James S. Blachly, Jennifer A. Woyach
Figure S1 shows immunoglobulin A, B, and M levels in treated patients over time Figure S2 shows investigator-assessed progression-free survival by CLL-IPI score and presence or absence of complex karyotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ecbd95eea50dde789f03387b686897
https://doi.org/10.1158/2159-8290.22535279.v1
https://doi.org/10.1158/2159-8290.22535279.v1
Publikováno v:
J Psychiatr Res
Social functioning is diminished among people early in the course of psychotic illnesses, and is likely influenced by the negative symptoms that accompany these disorders, including changes in motivation and experience of pleasure. Though social impa
Autor:
Nicholas J K Breitborde, David M. Weiss, Aubrey M. Moe, Anne C Wilson, Amanda M Stewart, Marybeth McDonald, Jacob G. Pine
Publikováno v:
Psychiatric Rehabilitation Journal. 44:284-290
Objective: Psychotic disorders are serious illnesses that are most amenable to early intervention. Though inpatient units are typically the first care setting for young people with psychosis, almost all early intervention work has been limited to out
Autor:
Kerry A. Rogers, David M. Weiss, Ying Huang, Jennifer A. Woyach, Lynne V. Abruzzo, Nyla A. Heerema, Christin Banks, Allison Dean, Cara Grantier, Barbara L. Andersen, Margaret S. Lucas, Jeffrey A. Jones, Gerard Lozanski, Seema A. Bhat, John C. Byrd, Farrukh T. Awan, Kami J. Maddocks, Amy S. Ruppert, Thomas R. Valentine
Publikováno v:
J Clin Oncol
PURPOSE The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS This phase II study te
Autor:
Nicholas Nelson, Brittney Keller-Hamilton, Andreas A. Teferra, Amy K. Ferketich, David M. Weiss, Aubrey M. Moe, Jacob G. Pine, Amanda J. Quisenberry, Tory H. Hogan, Nicholas J K Breitborde
Publikováno v:
Journal of Smoking Cessation
Introduction. Individuals with psychotic-spectrum disorders may smoke due to the ameliorating effect of nicotine on the cognitive deficits that accompany these illnesses. Metacognitive remediation therapy (MCR) has been shown to produce improvements
Autor:
David M. Weiss, Veerendra Munugalavadla, Barbara L. Andersen, Min Hui Wang, Kerry A. Rogers, Seema A. Bhat, James S. Blachly, Jennifer A. Woyach, Yan Xu, Adam Kittai, Mojgan Jianfar, Anna Butturini, Gerard Lozanski, Priti Patel, John C. Byrd, Michael R. Grever
Publikováno v:
Blood. 136:16-18
Background: Acalabrutinib (A) is a next-generation, highly selective, covalent Bruton tyrosine kinase (BTK) inhibitor approved for marketing by the US FDA in patients (pts) with chronic lymphocytic leukemia (CLL). While responses to A monotherapy are